Comments
The US Food and Drug Administration said on Tuesday that it may decline to review and process new emergency use authorisation (EUA) requests for Covid-19 vaccines for the rest of the pandemic, if a company has not already begun discussions.
So far, vaccines from Pfizer Inc, Moderna Inc and Johnson & Johnson have been authorised for emergency use in the US.
Ocugen submits ‘Master File’ to FDA on Covid vaccine Covaxin
Novavax Inc has had discussions with regulators and said it does not expect to seek regulatory authorisation for its Covid-19 shot in the US, Britain and Europe until the third quarter of 2021.
Medicago in discussions
Canadian drug developer Medicago said it was in discussions with the FDA for an EUA for its plant-based Covid-19 vaccine candidate, which is enhanced by a GlaxoSmithKline treatment.
US FDA gears up for rapid review of potential Covid-19 booster shots
AstraZeneca also has discussed plans for its Covid-19 vaccine with US officials. However, the Wall Street Journal earlier this month reported that it was considering skipping US emergency-use authorisation and instead pursue the more time-intensive application for a full-fledged licence to sell the shot.
AstraZeneca and Novavax did not immediately respond to requests for comment
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.